Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial

- October 21st, 2016

Biopharmaceutical company Abeona Therapeutics (NASDAQ: ABEO) has provided clinical results for an ongoing phase 1/2 trial fro ABO-102 (AAV-SGSH).

Biopharmaceutical company Abeona Therapeutics (NASDAQ: ABEO) has provided clinical results for an ongoing phase 1/2 trial fro ABO-102 (AAV-SGSH).

According to the press release:
“ABO-102 is well-tolerated in subjects injected with the low dose of 5E13 vp/kg ABO-102 with no treatment related adverse events or serious adverse events (SAEs). Following favorable review of the safety data by the independent Data Safety Monitoring Board (DSMB), enrollment in the high dose cohort has commenced.”

CEO Timothy J. Miller said the following:

“The data demonstrate an early and robust systemic delivery of ABO-102, and the reductions in CNS and urinary GAG support our approach for intravenous delivery of ABO-102 for subjects with Sanfilippo syndromes. We are excited about early biomarker signals in this trial, including the reductions in liver and spleen volumes.”

Read the complete press release here.

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply